← All indications
Schizophrenia
A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
Subtype terms (5)
More specific conditions that are subtypes of Schizophrenia in the MeSH hierarchy.
- Schizophrenia, Catatonic
1 drug approved
- Schizophrenia, Disorganized
2 drugs approved
- Schizophrenia, Paranoid
10 drugs (7 approved, 3 experimental)
- Schizophrenia, Treatment-Resistant
16 drugs (15 approved, 1 experimental)
- Shared Paranoid Disorder
Drugs by status
Approved for this indication (41)
- zuclopenthixol
- risperidone
- blonanserin
- clozapine
- brexpiprazole
- prochlorperazine
- olanzapine
- pipamperone
- sertindole
- fluphenazine
- samidorphan
- d-serine
- trifluoperazine
- carphenazine
- cariprazine
- perphenazine
- xanomeline
- haloperidol
- lurasidone
- quetiapine
- flupentixol
- fluspirilene
- bromperidol
- perospirone
- piperacetazine
- iloperidone
- lumateperone
- asenapine
- loxapine
- molindone
- +11 more
Phase 4 trials (103)
- pravastatin
- minocycline
- bazedoxifene
- fatty acid
- modafinil
- topiramate
- esomeprazole
- vitamin c
- icosapent ethyl
- berberine
- immune globulin (human)
- pimozide
- memantine
- oxytocin
- infliximab
- valaciclovir
- reboxetine
- rasagiline
- telmisartan
- fish oil
- fumarate
- valproic acid
- agomelatine
- vortioxetine
- trazodone
- amantadine
- propofol
- citalopram
- raloxifene
- celecoxib
- +73 more
Phase 3 trials (99)
- tiaprizal
- encenicline
- mianserin
- iti-007
- vitamin d3
- gabapentin
- sodium butyrate
- bi 425809
- theanine
- chlorprothixene
- hydroxyzine
- midazolam
- tryptophan
- Lormetazepam
- lisdexamfetamine
- atorvastatin
- nicotergoline
- Ulotaront
- bromazepam
- chloral hydrate
- zonisamide
- promethazine hydrochloride
- estradiol
- acetylsalicylic acid
- temazepam
- opipramol
- phenytoin
- levomepromazine
- levetiracetam
- triazolam
- +69 more
Phase 2 trials (124)
- oms643762
- resveratrol
- azd-2624
- tirzepatide
- azd8529
- luvadaxistat
- nitroprusside
- vildagliptin
- sb773812
- apo-methylphenidate
- dydrogesterone
- nrx-1074
- ceftriaxone
- Mardepodect
- hs-10380
- alicaforsen
- rl-007
- phosphatidylcholine
- 3-2,4 dimethoxybenzylidene
- dextrose
- azd-3480
- spg302
- tetrahydrocannabivarin
- prednisolone
- alto-101
- jx11502ma
- abt-126
- cellulose
- fingolimod
- asp4345
- +94 more
Phase 1 trials (60)
- htc-867
- iomazenil (123i)
- r-amphetamine
- urb597
- jnj-39393406
- amg 581
- tak-058
- furosemide
- roflumilast
- benserazide
- dpa-713
- aut00206
- zagociguat
- iti-214
- papaverine
- vv119
- cassia seed
- 123i-cns 1261
- fallypride
- riluzole
- gsk1144814
- ucb-j
- cannabis
- pf-04802540
- mk2637
- levothyroxine
- natalizumab
- pf-05180999
- moxifloxacin
- lipopolysaccharide
- +30 more
Other trials (47)
- lidocaine
- caffeine
- fluvastatin
- dextroamphetamine
- pbr111
- vasopressin
- methylfolate
- nitroglycerin
- hawthorn berry extract
- (r)-3-hydroxybutyl (r)-3-hydroxybutyrate
- pergolide
- tetrabenazine
- entacapone
- clonidine
- mecamylamine
- ergocalciferol
- luteolin
- yinhsing
- fiber
- gluten
- Lactobacillus acidophilus
- wheat
- physostigmine
- isradipine
- goserelin
- lemopromazine
- l-tetrahydropalmatine
- pioglitazone
- droperidol
- ginkgo biloba
- +17 more
Organizations
Organization Involved with Phase 4 Indications (228)
- University of Mannheim
- Seoul National University
- Chongqing Medical University
- Beer-Yaacov MHC
- American Legion of Iowa Foundation
- Medical University of Lodz
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- National Institute on Drug Abuse (NIDA)
- University of Medicine and Dentistry of New Jersey
- Amanuel Mental Hospital, Addis Ababa, Ethiopia
- University of London
- University of Missouri, Kansas City
- University of Tuebingen
- Monash University
- University of Maryland
- Capital Medical University
- McMaster University
- University of Georgia
- University of Miami
- Martin Luther University
- Ram Manohar Lohia Insitute of Medical Sciences
- Cha Medical University
- Indiana University
- Dartmouth University
- Beer Yaakov and Ness Ziona Mental Health Center
- University of Montreal
- Julius-Maximilians University
- Soonchunhyang University
- Federal University of Rio Grande do Sul
- Emek Medical Center
- +198 more
Organization Involved with Phase 3 Indications (100)
- Gedeon Richter Ltd.
- Amarex Clinical Research
- Shire
- Roche
- Geestelijke gezondheidszorg voor mensen in Eindhoven en omgeving
- Shipowner Emil Stray's legacy
- Donaghue Foundation
- Taipei Veteran General hospital
- Laxdale Ltd
- BioLineRx, Ltd.
- Johanne and Einar Eilertsen's research fund
- University of Oslo
- Medistat Ltd., Israel
- Ospedale Unico della Versilia
- Norwegian University of Science and Technology
- Clinic for Psychiatric Disorders
- Baylor University
- Braeburn Pharmaceuticals
- Clinic for Psychiatric Disorders, Dr Laza Lazarevic
- Herzog Hospital
- Noven Therapeutics
- Karolinska Institute
- UMC Utrecht
- Solveig and Johan P. Sommer's foundation
- St Tydfil's Hospital
- S.C. IMUNOTEHNOMED S.R.L.
- Desert Pacific Mental Illness Research, Education, and Clinical Center
- Government of Thailand
- National Cheng Kung University
- Gottfried Wilhelm Leibniz Universität Hannover
- +70 more
Organization Involved with Phase 2 Indications (113)
- Camden and Islington NHS Foundation Trust
- CoMentis
- Sheppard Pratt Health System
- Triumpharma
- University of Florence
- Innovative Clinical Research, Inc.
- Repligen Corporation
- Arvelle
- American Medical Research
- Concert Pharmaceuticals
- Biogen
- Dow University of Health Sciences
- University of Birmingham
- Pharmathen S.A.
- Government of Pakistan
- Lyndra Inc.
- Centers for Behavioral Health, LLC
- Florida Clinical Research Center, LLC
- German Research Foundation
- Guilin University
- Uppsala University
- Northern Ontario School of Medicine
- University of Puerto Rico
- Woodbury, Michel
- American Heart Association
- Sadat City University
- Laureate Institute for Brain Research
- Virginia Commonwealth University
- North East London Foundation Trust
- Memory Pharmaceuticals
- +83 more
Organization Involved with Phase 1 Indications (49)
- Autifony Therapeutics Limited
- American Psychiatric Foundation
- Torrent Pharmaceuticals Limited
- PPD
- Cadent Therapeutics
- National University of Malaysia
- Quotient
- Shin Nippon Biomedical Laboratories
- Catholic University of Korea
- Calo Psychiatric Center
- University of Tabriz
- Compass Research
- Wonkwang University
- Dongguk University
- Cerevance
- Naju National Hospital
- bioRASI, LLC
- University of Arizona
- CMG Pharmaceutical Co. Ltd
- Konkuk University
- West Pharmaceutical Services
- LB Pharmaceuticals Inc.
- DongWha Pharmaceutical Company
- University of Vermont
- Orebro University
- Taisho Pharmaceutical
- National Cancer Institute (NCI)
- Anhui Medical University
- Weston Havens Foundation
- Wuhan Psychiatric Hospital
- +19 more
Organization Involved with Other Experimental Indications (55)
- Robert Wood Johnson Foundation
- KhonKaen University
- University of Monastir
- Guang Dong Provincial Mental Health Institute
- McPin Foundation
- Chhatrapati Sahuji Maharaj Medical University
- National Center for Research Resources (NCRR)
- University of Zurich
- Xianyang Central Hospital
- Burrell Behavioral Health
- Government of China
- Hacettepe University
- Government of Ontario
- Arthur P. Noyes Research Foundation
- Canadian Psychiatric Research Foundation
- University of Illinois
- Hôpital le Vinatier
- University of Florida
- Royal Liverpool & Broadgreen University Hospitals NHS Truts
- Government of Canada
- The Bowman Family Foundation
- Free University of Amsterdam
- University of Colorado
- Zucker Hillside Hospital
- Hanzhong Central Hospital
- Florida Atlantic University
- Dalhousie University
- Liverpool John Moores University
- University of Texas, San Antonio
- Government of Denmark
- +25 more